11 Results for "

HCC70

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "HCC70" in MCE Product Catalog:

7
7 Cited Publications
Cat. No.: HY-138293
CAS No.: 2417302-07-7
Purity:  99.33%
Synonyms: CDK7-IN-3
Target:  

CDK Apoptosis

Research Areas:  

Cancer

SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent CDK7 inhibitor with a KD of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (Ki=2600 nM), CDK9 (Ki=960 nM), CDK12 (Ki=870 nM). SY-5609 induces apoptosis in tumor cells and has antitumor activity .
loading...
    loading...
Cat. No.: HY-122665
CAS No.: 2000209-42-5
Purity:  98.64%
Research Areas:  

Cancer

HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 can be uesd for breast cancer research .
loading...
    loading...
Cat. No.: HY-172957
Target:  

JAK

Research Areas:  

Cancer

JNN-5 is a potent and selective JAK2 inhibitor with an IC50 of 0.41 nM. JNN-5 shows strong antiproliferative activities in the TNBC cell lines (MDA-MB-468, MDA-MB-213, HCC70, MDA-MB-157) .
loading...
    loading...
Cat. No.: HY-145389
CAS No.: 2654003-68-4
Target:  

CDK

Research Areas:  

Cancer

SZ-015268 is a CDK7 inhibitor with an IC50 of 23.56 nM. SZ-015268 has extremely significant anti-tumor advantages. SZ-015268 inhibits HCC70, OVCAR-3, HCT116 and HCC1806 cells proliferation with IC50s of 33, 80.56, 12.53, and 61.55 nM, respectively .
loading...
    loading...
Cat. No.: HY-122665A
Purity:  98.01%
Research Areas:  

Cancer

HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 TFA can be uesd for breast cancer research .
loading...
    loading...
Cat. No.: HY-164349
CAS No.: 2416196-47-7
Target:  

STAT

Research Areas:  

Cancer

WZ-2-033 is a potent STAT3 inhibitor. WZ-2-033 inhibits MDA-MB-231, HCC70, and MDA-MB231-4175 cells proliferation, colony survival, migration, and invasion with IC50s of 0.7, 1.3, and 1.3 μM, respectively .
loading...
    loading...
Cat. No.: HY-W743405
CAS No.: 4651-48-3
Stigmasterol acetate is a Stigmasterol (HY-N0131) derivative. Stigmasterol acetate can be used in the research of breast cancer .
loading...
    loading...
Cat. No.: HY-180355
CAS No.: 2365230-48-2
Research Areas:  

Cancer

SY-5102 is a potent, selective and orally active cyclin-dependent kinase (CDK7) inhibitor with a Kd of 0.03 nM. SY-5102 shows anti-proliferative activity against HCC70 cells with an EC50 of 9 nM. SY-5102 can inhibit CDK7-mediated CAK function (downregulate CDK2 Thr160 phosphorylation) and TFIIH transcription function (downregulate RNA polymerase II Ser5 phosphorylation). SY-5102 can induce G2/M cell cycle arrest, downregulate the expression of the oncogene c-Myc, and ultimately trigger cancer cell apoptosis. SY-5102 can be used for the research of triple-negative breast cancer (TNBC) .
loading...
    loading...
Cat. No.: HY-169344
CAS No.: 2943043-62-5
Target:  

CDK

Research Areas:  

Cancer

CDK7-IN-31 (compound 13) is a potent and orally active cyclin-dependent kinase 7 (CDK7) inhibitor with a Kd value of 0.18 nM. CDK7-IN-31 shows anticancer activity .
loading...
    loading...
Cat. No.: HY-184273
CAS No.: 1903103-73-0
Research Areas:  

Cancer

TH-407a is an orally active and selective USP15 inhibitor with an IC50 of 0.76 μM. As an allosteric modulator, TH-407a binds to a non-catalytic site to block deubiquitinating activity. TH-407a inhibits cell growth, proliferation, clonogenicity and migration, regulates the p53 signaling pathway, and reduces the stability of PARP1. TH-407a exhibits anti-tumor activity in breast cancer xenograft mouse models. TH-407a can be used for the research of breast cancer .
loading...
    loading...
Cat. No.: HY-19926A
CAS No.: 1778671-05-8
Synonyms: RG-7602 hydrochloride
Research Areas:  

Cancer

GDC-0425 hydrochloride (RG-7602 hydrochloride) is an orally active, highly selective ChK1 inhibitor. GDC-0425 hydrochloride abrogates cell cycle arrest and inhibits genomic repair. GDC-0425 hydrochloride potently suppresses Gemcitabine (HY-17026)-induced pCDK1/2 expression. GDC-0425 hydrochloride can be used in research related to osteosarcoma, ovarian cancer, basal (triple-negative) breast cancer, and colorectal cancer .
loading...
    loading...
  • 1